HCA
Not exactly a vote of no confidence
Deroy & Devereaux Private Investment Counsel shaved 5% off its HCA position in the fourth quarter, but don’t mistake that for a dramatic breakup. The fund still owns 111,274 shares, and HCA remains its third-largest holding worth roughly $51.95 million — basically the portfolio equivalent of saying, “We’re cutting back, not ghosting.”
The real headline: HCA keeps doing HCA things
The filing lands alongside a stronger-than-expected earnings update, where HCA posted $8.01 in EPS and $19.51 billion in revenue. Revenue still grew 6.7% year over year, which is the kind of “business is fine, thanks” signal investors like to see in a healthcare name with a big, recurring demand story.
Why investors should care
What makes this more interesting is the company’s FY2026 guidance: HCA sees EPS between 29.10 and 31.50, while analysts are sitting closer to 24.98. That’s a pretty chunky gap, and when management’s numbers are running ahead of the Street, the stock tends to notice.
Also in the background: insiders were selling
The article also flags insider selling, including 15,214 shares worth about $7.8 million in the last quarter and a February sale by EVP Michael R. McAlevey. That doesn’t automatically mean trouble — executives do sell for lots of reasons — but it does add a little extra seasoning to the story.
Big picture: this isn’t a blockbuster drama, but it does show HCA still has institutional support, strong earnings momentum, and guidance that could keep investors leaning forward instead of checking out.